Login / Signup

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial.

Gideon M HirschfieldKatherine ArndtzAmanda KirkhamYung-Yi ChenRichard FoxAnna RoweJessica Douglas-PughDouglas ThorburnEleanor BarnesGuruprasad P AithalDiana HullKhushpreet BhandalKathryn OlsenPaul WoodwardSiân LaxPhilip Noel NewsomeDavid J SmithAntero KallioDavid H AdamsVictoria HomerChristopher J Weston
Published in: Hepatology communications (2024)
The BUTEO trial confirmed 8 mg/kg timolumab had no short-term safety signals and resulted in sufficient circulating levels of VAP-1 blocking timolumab. However, the trial was stopped after an interim assessment due to a lack of efficacy as determined by no significant change in serum liver tests.
Keyphrases